At least two companies are preparing to take inducers of tertiary lymphoid structure into the clinic
Product Development
Discovery & Translation
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
Politics, Policy & Law
Government now on brink of shutdown
Finance
Biotech likely to remain under macroeconomic pressure as Fed halves projections for interest rate cuts next year
Management Tracks
Plus: Ra capital names three new partners and updates from Anaveon, Adicet, Bio Usawa and Neopredics
BioCentury ISSN 1097-7201